Understanding how cells decide between a quiet death and an inflammatory one has enormous implications for cancer therapy, autoimmune disease, and age-related inflammation. A newly resolved atomic-level picture of a key cell-death protein now offers a structural explanation for that decision — and reveals a molecular switch that controls it.
Gasdermin E (GSDME) sits at a critical crossroads: when cleaved by caspase-3 during classical apoptosis, its N-terminal domain can insert into the plasma membrane and assemble into large pores, converting a non-inflammatory death into pyroptosis — an explosive, cytokine-releasing form of cell death. Using cryo-electron microscopy, investigators determined the high-resolution architecture of the assembled GSDME pore, establishing the stoichiometry and conformational rearrangements that drive membrane insertion. Critically, they also demonstrated that S-palmitoylation — the reversible attachment of a fatty acid chain to a cysteine residue — acts as a structural brake, sterically blocking the conformational transition required for pore assembly and thereby suppressing pyroptosis.
This work fills a meaningful gap in the gasdermin structural canon. While cryo-EM structures of GSDMD pores have existed since the late 2010s, GSDME's pore architecture had remained unresolved despite its distinct biological context — including its paradoxical role in chemotherapy-induced tumor cell death and its expression in neurons and cochlear hair cells, where dysregulated pyroptosis drives hearing loss. The palmitoylation finding is particularly notable: it suggests that lipid modification enzymes (DHHC acyltransferases and APT thioesterases) upstream of GSDME could serve as druggable targets to tune inflammatory cell death intensity without eliminating it entirely. Limitations include the absence of cellular validation of the palmitoylation mechanism in physiologically relevant models, and it remains to be seen whether therapeutic modulation of this switch translates across tissue contexts. Nonetheless, this structural framework is likely to guide the rational design of GSDME-targeting compounds for inflammatory and oncological indications.